Gurusowmyasri Kota,
- Student, Department of Biotechnology, Garden City University, University in Bengaluru, Karnataka, India
Abstract
Aim: Rheumatoid arthritis (RA) is a long-term autoimmune condition characterized by the immune system mistakenly attacking the joints, leading to swelling, discomfort, and joint deformities. Current management strategies include anti-rheumatic drugs and biologics, which have limitations. This study aims to explore the therapeutic potential of Ricinus communis (castor bean plant) phytochemicals as plant-based therapies for autoimmune conditions, like RA. Methods: Phytochemicals from Ricinus communis were retrieved using the IMPPAT database, identifying 95 compounds. Their drug-like properties were evaluated using the SwissADME tool, resulting in the selection of seven compounds: Ricinine, Apigenin, Glycolic acid, Shikimic acid, Nicotinamide, threo-9, 10-Dihydroxystearic acid, and uric acid. Toxicity assessments were conducted using the protox tool. Molecular docking was performed with pyrx to evaluate interactions was achieved using BIOVIA. Results: This study revealed that Ricinus communis Phytochemicals demonstrated strong binding affinities with autoimmune pathway-related proteins 1A8M and 1TNF, indicating significant anti-inflammatory and immunomodulatory potential. These findings suggest their promise as plant-based therapeutic agents for RA. Conclusion: This research underscores the promising anti-inflammatory and immunomodulatory properties of phytochemicals derived from Ricinus communis. The identified compounds exhibit favorable drug-like and safety profiles, with significant binding to autoimmune pathway-related proteins. These findings provide a foundation for experimental studies and the development of plant-based therapies for autoimmune disorders, such as RA.
Keywords: Rheumatoid arthritis, Ricinus communis, phytochemicals, autoimmune disorders, molecular docking, anti-inflammatory, immunomodulatory
[This article belongs to International Journal of Bioinformatics and Computational Biology ]
Gurusowmyasri Kota. Exploring Phytochemicals from Ricinus Communis for Potential Therapeutic Applications in Rheumatoid Arthritis: An in-Silico Approach. International Journal of Bioinformatics and Computational Biology. 2025; 03(01):32-41.
Gurusowmyasri Kota. Exploring Phytochemicals from Ricinus Communis for Potential Therapeutic Applications in Rheumatoid Arthritis: An in-Silico Approach. International Journal of Bioinformatics and Computational Biology. 2025; 03(01):32-41. Available from: https://journals.stmjournals.com/ijbcb/article=2025/view=197271
References
1. Radu AF, Bungau SG. Management of rheumatoid arthritis: An overview. Cells. 2021;10(11):2857. doi: 10.3390/cells10112857.
2. Firestein GS. Evolving concepts of rheumatoid arthritis. Nature. 2003;423(6937):356–361. doi: 10.1038/nature01661.
3. Grassi W, De Angelis R, Lamanna G, Cervini C. The clinical features of rheumatoid arthritis. Eur J Radiol. 1998;27 Suppl 1:S18–S24. doi: 10.1016/s0720-048x(98)00038-2.
4. Bastos LL, Mariano D, Lemos RP, Bialves TS, Oliveira CJ, de Melo-Minardi RC. The role of structural bioinformatics in understanding tumor necrosis factor α-interacting protein mechanisms in chronic inflammatory diseases: A review. Struct Immunol. 2024;4(1):14–42. doi: 10.3390/immuno4010002.
5. Wu H, Hymowitz SG. Structure and function of tumor necrosis factor (TNF) at the cell surface. In: Handbook of Cell Signaling. Academic Press; 2010. pp. 265–275.
6. Naji RA, AL-Daher RI, Abood DA, Madlum KN. Immunological impact of Ricinus communis leaves extract on isolated human peripheral blood mononuclear cells. Med J Babylon. 2023;20(1):120–123. doi: 10.4103/MJBL.MJBL_287_22.
7. Jena J, Gupta AK. Ricinus communis Linn: a phytopharmacological review. Int J Pharm Pharm Sci. 2012;4(4):25–29.
8. Tarachand SP, Thirumoorthy G, Lakshmaiah VV, Nagella P. In silico molecular docking study of Andrographis paniculata phytochemicals against TNF-α as a potent anti-rheumatoid drug. J Biomol Struct Dyn. 2023;41(7):2687–2697. doi: 10.1080/07391102.2022.2037463.
9. Bai LL, Chen H, Zhou P, Yu J. Identification of tumor necrosis factor-alpha (TNF-α) inhibitor in rheumatoid arthritis using network pharmacology and molecular docking. Front Pharmacol. 2021;12:690118. doi: 10.3389/fphar.2021.690118.
10. Morris GM, Lim-Wilby M. Molecular docking. Methods Mol Biol. 2008:443:365–382. doi: 10.1007/978-1-59745-177-2_19.
11. Agarwal S, Mehrotra RJ. An overview of molecular docking. JSM Chem. 2016;4(2):1024–1028.
12. Available at https://www.researchgate.net/profile/Shweta-Agarwal-7/publication/303897563_
Mini_Review_An_overview_of_Molecular_Docking/links/575b9fb108aed884620da00a/Mini-Review-An-overview-of-Molecular-Docking.pdf
13. Gschwend DA, Good AC, Kuntz ID. Molecular docking towards drug discovery. J Mol Recognit. 1996;9(2):175–186. doi: 10.1002/(sici)1099-1352(199603)9:23.0.co;2-d.
14. Elokely KM, Doerksen RJ. Docking challenge: Protein sampling and molecular docking performance. J Chem Inf Model. 2013;53(8):1934–1945. doi: 10.1021/ci400040d.
| Volume | 03 |
| Issue | 01 |
| Received | 27/12/2024 |
| Accepted | 11/01/2025 |
| Published | 06/02/2025 |
| Publication Time | 41 Days |
Login
PlumX Metrics